Tempus AI, Inc. (NASDAQ: TEM) received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH. The AI-enabled software analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension.

This approval marks the third FDA-cleared device in Tempus’ cardiovascular portfolio. The company stated the product expands its suite of next-generation AI products aimed at identifying patients at risk for complex cardiac conditions.

Regulatory Milestone

The FDA clearance validates the clinical utility of Tempus ECG-PH as a diagnostic aid. By leveraging standard 12-lead ECGs, the tool aims to streamline the detection process for pulmonary hypertension, a condition often difficult to diagnose early.

Portfolio Expansion

Tempus positions this device within a broader strategy to integrate AI into routine clinical workflows. As the third entry in its cardiovascular segment, Tempus ECG-PH complements existing offerings, reinforcing the company’s focus on complex cardiac risk identification.

Tempus AI Inc (NASDAQ: TEM) shares climbed 5.09% to $70.04 on Friday, extending gains from Thursday’s premarket rally. The move follows continued investor digestion of positive Phase 3 clinical trial results from Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) for a personalized mRNA cancer vaccine.

The rally underscores the strategic value of Tempus AI’s pending $1.5 billion acquisition of Personalis Inc. Investors are linking the clinical success directly to Personalis’s sequencing platform, which is critical for manufacturing the custom vaccine doses used in the trial.

Clinical Trial Milestone

The catalyst remains the INTerpath-001 study results announced earlier in the week. The trial evaluated intismeran autogene, a customized mRNA-based individualized neoantigen therapy, in combination with Keytruda. The combination significantly improved recurrence-free survival in patients with resected melanoma.

This result marks the first successful Phase 3 readout for a customized mRNA-based cancer treatment. For Moderna, it validates its platform beyond pandemic-era origins. For Tempus AI, it confirms the commercial and technological relevance of the assets it is acquiring from Personalis.

The Personalis Connection

Moderna relies on Personalis’s sequencing platform to analyze patient tumor tissue and identify specific neoantigens required for manufacturing custom vaccine doses. This technological dependency makes the clinical success highly material for Tempus AI.

Tempus AI previously partnered with Personalis to commercialize minimal residual disease tests. By acquiring Personalis for $1.5 billion, Tempus inherits the critical sequencing infrastructure supporting Moderna’s therapeutic program as it achieves this major clinical milestone.

Tempus CEO Eric Lefkofsky highlighted the connection on social media Wednesday, congratulating Moderna and Merck while noting Tempus’s pride in supporting the breakthrough program.

Technical Analysis

At $70.04, Tempus AI is trading significantly above its trend gauges. The stock is up approximately 33% above its 20-day simple moving average (SMA) of $51.08 and 19.7% above its 200-day SMA of $56.75.

The Relative Strength Index (RSI) stands at 71.53, placing the stock in overbought territory. This typically signals that the move is stretched and upside may become harder to sustain without a reset. The broader technical picture remains mixed, with the 50-day SMA remaining below the 200-day SMA following a death cross in January.

Traders may watch $76.50 as near-term resistance where rebounds can stall. Meanwhile, $61.50 serves as key support, defining whether any pullback stays controlled.

What the Numbers Show

The divergence between Tempus AI’s technical indicators and its price action highlights strong fundamental validation overriding technical headwinds. While the RSI of 71.53 suggests overbought conditions and the stock trades well above its 20-day SMA ($51.08), the price has surged to $70.04. This indicates that investors are prioritizing the strategic utility of the Personalis acquisition—validated by the blockbuster oncology trial—over short-term momentum risks.